Contact Us
Drug Search Results
More Filters [+]

Etripamil

Alternative Names: etripamil
Latest Update: 2025-01-07
Latest Update Note: News Article

Product Description

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical,Nasal

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Milestone
Company Location: MONTREAL A8 H4M 2X6
Company CEO: Joseph Oliveto
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Etripamil

Countries in Clinic: Argentina, Brazil, Canada, China, Colombia, Germany, Netherlands, Spain, United States

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Atrial Fibrillation|Tachycardia, Paroxysmal|Tachycardia, Supraventricular|Tachycardia, Ventricular

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MSP-2017-1265

P2

Unknown Status

Tachycardia, Supraventricular|Tachycardia, Paroxysmal|Tachycardia, Ventricular

2027-06-30

MSP-2017-1265

P2

Recruiting

Tachycardia, Ventricular|Tachycardia, Supraventricular|Tachycardia, Paroxysmal

2027-06-01

ReVeRA-301

P3

Not yet recruiting

Atrial Fibrillation

2027-03-01

2022-001854-49

P2

Active, not recruiting

Atrial Fibrillation

2025-11-01

Recent News Events

Date

Type

Title

01/07/2025

News Article

 Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12/23/2024

News Article

 CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes

09/24/2024

News Article

 Milestone Pharmaceuticals to Host Investor KOL Event

09/06/2024

News Article

 Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

05/21/2024

PubMed

 Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion.

05/08/2024

PubMed

 Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia.

02/01/2024

PubMed

 Plain language summary of the safety and effectiveness of etripamil for atrioventricular-nodal-dependent supraventricular tachycardia: the RAPID study.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions